• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYP

CYNATA THERAPEUTICS LIMITED - News & Media

2.86% ! 17.0¢
Market Cap $38.41M  !
Healthcare Biotechnology
Add to My Watchlist

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

Articles & Videos

Cynata's stem cell tech verified in peer-reviewed study

Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified as similar to convention MSCs in a study published in a peer-review journal.

05 Feb 2025 11:45 (AEDT)

Cynata study shows efficacy of stem-cell therapy on chronic lung disease

Cynata Therapeutics Ltd has published a study examining the effect of its Cymerus therapy on idiopathic pulmonary fibrosis symptoms.

08 Aug 2024 12:51 (AEST)

Cynata wins EU ethics approval for phase 2 Trial of CYP-001

Cynata Therapeutics has been given EU regulatory and ethics approval for phase 2 Trial of its latest development 'CYP-001'

20 Mar 2024 10:44 (AEDT)

Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment

The market has responded favourably to Cynata Therapeutics' announcement regarding its Phase 2 clinical trial on graft versus host disease.

05 Mar 2024 15:38 (AEDT)

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase II clinical trial using its drug candidate, CYP-001.

07 Dec 2023 13:04 (AEDT)

Cynata Therapeutics (AX:CYP) announces CEO succession and board changes

Cynata Therapeutics (ASX:CYP) has appointed Dr Kilian Kelly as its CEO and Managing Director, effective from July 1.

30 Jun 2023 15:15 (AEST)

Cynata Therapeutics (ASX:CYP) receives approval for acute graft-versus-host disease clinical trial

Cynata Therapeutics (ASX:CYP) has received approval to launch a proposed phase two clinical trial of acute graft-versus-host disease.

30 Jan 2023 14:49 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
17.0¢ 		Change
-0.005(2.86%) 		Mkt cap ! $38.41M
Open High Low Value Volume
18.0¢ 18.0¢ 16.5¢ $41.91K 247.1K

Buyers (Bids)

No. Vol. Price($)
2 8275 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 3700 1
View Market Depth
Last trade - 16.10pm 30/07/2025 (20 minute delay) ?
Last
17.0¢ 		  Change
-0.005 ( 5.56 %)
Open High Low Volume
17.0¢ 17.0¢ 16.5¢ 80790
Last updated 13.12pm 30/07/2025 ?
CYP (ASX) Chart

Top Stories

Neurizon inks $1.5M loan against R&D Tax Rebate

Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic Let’s check in with what HotCopper users are closely watching at lunchtime. Given that we’re basically on the deadline before companies get a scolding if they don’t report updates, on Wednesday, the ASX announcements list is basically one big wall o...
Haranga jumps +7% on Lincoln acquisition Haranga Resources (ASX:HAR) has spiked in intra-day trade after closing the acquisition of the Lincoln Gold Project in California.The Lincoln Project traverses 322 hectares and covers a strike length of the Mother Lode with 5.8km between Sutter Creek and Amador City. It boasts a gold resource of ...
ASX Market Close: Index rebounds as investors buoyant | July 30, 2025 The ASX200 rebounded today and was in the green heading into the close. Investors were buoyant in response to positive inflation data that increased the odds of an interest rate cut in August.Staples, Real Estate and Discretionary were the strongest performing sectors. Utilities and IT were a dra...
Ionic Rare Earths falls -7% as momentum slips on vague production update Ionic Rare Earths (ASX:IXR) @ a well-known and much-loved rare earths darling on something of a comeback run lately @ has slipped -7%, presumably as the market digests what a vague update released on Wednesday actually means. According to the company, @urgent supply requests from US, European and...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.